PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

vorapaxar

Verify with FDA → · CMS NADAC pricing →

Brand names: Zontivity

PAR-1 Antagonist (Antiplatelet) Rx

Vorapaxar (Zontivity) helps prevent blood clots if you have had a heart attack or have peripheral artery disease. It works by stopping platelets in your blood from sticking together and forming clots.

What it does

Vorapaxar is used to lower the chance of having serious heart problems if you have a history of heart attack or peripheral artery disease (PAD).

Common side effects

Bleeding

Key warnings

Vorapaxar can cause serious bleeding, including bleeding in the brain, which can be fatal.

How It Works

Vorapaxar is a PAR-1 antagonist, which means it blocks a specific receptor on platelets. This receptor, called protease-activated receptor-1 (PAR-1), normally causes platelets to clump together. By blocking PAR-1, vorapaxar helps prevent blood clots from forming.

How to Take It

Take one 2.08 mg vorapaxar tablet once a day. You can take it with or without food. Vorapaxar should be used with aspirin and/or clopidogrel, as directed by your doctor. Talk to your doctor if you have any questions about how to take vorapaxar.

Pregnancy & Breastfeeding

It is not known if vorapaxar will harm an unborn baby. Talk to your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.

Missed Dose

If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and take your next dose at the regular time.

Storage

Store the tablets at room temperature (68-77°F) in the original package, tightly closed, and protected from moisture. Keep the desiccant in the bottle.

Serious Warnings

Vorapaxar can cause serious bleeding, including bleeding in the brain, which can be fatal. You should not take this medicine if you have a history of stroke, transient ischemic attack (TIA), or bleeding in the brain. Also, do not take it if you have active bleeding.

Known Drug Interactions

Strong CYP3A Inhibitors Avoid concomitant use of ZONTIVITY with strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, posaconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, boceprevir, telaprevir, telithromycin and conivaptan) [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3) ] .

Mechanism: Ketoconazole blocks the enzyme that breaks down vorapaxar, which can cause the drug to build up to high levels in your body.

What to do: Do not take these two medications together.

Strong CYP3A Inducers Avoid concomitant use of ZONTIVITY with strong inducers of CYP3A (e.g., rifampin, carbamazepine, St.

Mechanism: Carbamazepine speeds up how fast your body gets rid of vorapaxar, which can make the drug less effective.

What to do: Avoid using these two medicines at the same time.

Strong CYP3A Inhibitors Avoid concomitant use of ZONTIVITY with strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, posaconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, boceprevir, telaprevir, telithromycin and conivaptan) [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3) ] .

Mechanism: Clarithromycin stops your body from processing vorapaxar correctly, leading to higher amounts of the drug in your blood.

What to do: You should avoid taking these two drugs together.

moderate rifampin

Strong CYP3A Inducers Avoid concomitant use of ZONTIVITY with strong inducers of CYP3A (e.g., rifampin, carbamazepine, St.

Mechanism: Rifampin causes your body to break down vorapaxar too quickly, which may prevent the medicine from working as it should.

What to do: Do not use these two medications together.

Strong CYP3A Inhibitors Avoid concomitant use of ZONTIVITY with strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, posaconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, boceprevir, telaprevir, telithromycin and conivaptan) [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3) ] .

Mechanism: Posaconazole interferes with the way your body clears vorapaxar, which can lead to an unsafe buildup of the medication.

What to do: Avoid using this combination of drugs.

Check all your medications →

Common Questions

Can I take vorapaxar by itself?
No, vorapaxar should be taken with aspirin and/or clopidogrel.
What should I do if I notice unusual bleeding?
Tell your doctor right away if you have any unusual bleeding or bruising.
Can I drink alcohol while taking vorapaxar?
Talk to your doctor about whether it is safe for you to drink alcohol while taking vorapaxar.
Will vorapaxar stop working right away if I stop taking it?
No, vorapaxar's effects on platelets can last for about 4 weeks after you stop taking it.
What if I need surgery?
Talk to your doctor about whether you should stop taking vorapaxar before any surgery or procedure.
Can I take other medicines with vorapaxar?
Avoid taking vorapaxar with strong CYP3A inhibitors or inducers. Tell your doctor about all the medicines you take.
What are the signs of a stroke?
Signs of a stroke include sudden numbness or weakness, confusion, trouble speaking, or severe headache.
How does vorapaxar affect my risk of bleeding?
Vorapaxar increases your risk of bleeding. Your doctor will assess your risk factors before you start taking it.
What should I do if I am hypotensive after a heart procedure?
Tell your doctor immediately if you experience low blood pressure after a heart procedure.
Is there a way to reverse the effects of vorapaxar if I bleed?
No, there is no known treatment to reverse the antiplatelet effect of vorapaxar.
What are the common side effects of vorapaxar?
The most commonly reported side effects of vorapaxar include Bleeding. Always consult your healthcare provider about potential side effects.
Does vorapaxar interact with other medications?
Yes, vorapaxar has 8 known drug interactions. Notable interactions include ketoconazole, carbamazepine, clarithromycin. Always inform your doctor about all medications you are taking.
What drug class is vorapaxar?
vorapaxar belongs to the PAR-1 Antagonist (Antiplatelet) drug class. It requires a prescription (Rx). Vorapaxar is used to lower the chance of having serious heart problems if you have a history of heart attack or peripheral artery disease (PAD).
Is vorapaxar safe during pregnancy?
It is not known if vorapaxar will harm an unborn baby. Talk to your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. Always consult your healthcare provider before using any medication during pregnancy or breastfeeding.

Related Medications in PAR-1 Antagonist (Antiplatelet)

Other drugs grouped near vorapaxar — same-class peers and common alternatives.

Compare vorapaxar vs apixaban side-by-side →

Medication Guides

Related Health & Safety Data

Save on vorapaxar

Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.

Disclosure: This link may earn us a commission at no extra cost to you. See our terms.

What the FDA Data Shows for vorapaxar

The FDA label for vorapaxar (sold under brand names such as Zontivity) classifies it as a prescription-only medication in the PAR-1 Antagonist (Antiplatelet) class. Vorapaxar is used to lower the chance of having serious heart problems if you have a history of heart attack or peripheral artery disease (PAD). Official labeling lists 1 commonly reported side effect, including Bleeding.

Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. Voluntary reports accumulate over the lifetime of a drug and reflect wide-ranging clinical use. The database also lists 8 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated moderate severity. Acquisition-cost data is surveyed weekly by CMS and updated as manufacturers report changes.

Report counts do not establish causation — a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information further shape supply and switching decisions. This page summarizes public FDA data for educational purposes only and is not a substitute for professional medical advice — always consult a licensed healthcare provider before starting, stopping, or changing any medication.

Data Sources

Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS).

FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. Always consult a healthcare professional before making medication decisions.

Last updated: April 21, 2018

All federal data sources used on this page